CA Patent

CA2640974A1 — Method of treating chronic kidney disease

Assigned to Panion and BF Biotech Inc · Expires 2007-08-09 · 19y expired

What this patent protects

The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.

USPTO Abstract

The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.

Drugs covered by this patent

Auryxia (FERRIC CITRATE) · Keryx Biopharms

Patent Metadata

Patent number: CA2640974A1
Jurisdiction: CA
Classification: —
Expires: 2007-08-09
Drug substance claim: No
Drug product claim: No
Assignee: Panion and BF Biotech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.